{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:46:29Z","timestamp":1795052789953,"version":"4.10.2"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Rash is one of the most common adverse events observed with mogamulizumab, an anti-C-C chemokine receptor 4 monoclonal antibody approved for previously treated mycosis fungoides (MF) and Sezary syndrome (SS). Given the nonspecific clinical presentations of this rash, histopathologic distinction from MF\/SS is critical for informing clinical management. We performed a comprehensive characterization of the histopathologic findings in mogamulizumab-associated rash (MAR) with the integration of high-throughput sequencing of T-cell receptor (TCR) genes. Fifty-two biopsy specimens from 19 patients were evaluated retrospectively. Three major histologic reaction patterns were identified: spongiotic\/psoriasiform dermatitis (33\/52), interface dermatitis (11\/52), and granulomatous dermatitis (8\/52). Almost half of the specimens (21\/52) showed at least 2 of these reaction patterns concurrently. Dermal eosinophils were not a consistent feature, being present in only half (27\/52) of specimens and prominent in only 3. Features mimicking MF\/SS, including lymphocyte exocytosis, lamellar fibroplasia, and adnexal involvement, were commonly seen but tended to be focal and mild. In 38\/43 specimens with available immunohistochemistry, intraepidermal lymphocytes demonstrated a CD4:CD8 ratio \u22641\u2009:\u20091. Low background levels of the patient\u2019s previously identified MF\/SS-associated TCR sequence(s) were demonstrated in 20\/46 specimens analyzed by high-throughput sequencing of TCR. We conclude that MAR may demonstrate diverse histologic features. Findings that may distinguish MAR from MF\/SS include the inverted or normalized CD4:CD8 ratio within intraepidermal lymphocytes and demonstration of absent or nondominant levels of disease-associated TCR sequences. Correlation with the clinical findings and immunohistochemical and molecular characterization of the patient\u2019s MF\/SS before mogamulizumab, when possible, may facilitate recognition of MAR.<\/jats:p>","DOI":"10.1097\/pas.0000000000001587","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:04:12Z","timestamp":1601049852000},"page":"1666-1676","source":"Crossref","is-referenced-by-count":49,"title":["Histopathologic Characterization of Mogamulizumab-associated Rash"],"prefix":"10.1097","volume":"44","author":[{"given":"Jennifer Y.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey E.","family":"Hirotsu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana M.","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam S.","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryanne A.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Novoa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri E.","family":"Rieger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J Invest Dermatol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and sezary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J Hematol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.14634","article-title":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma","volume":"181","author":"Tokunaga","year":"2018","journal-title":"Br J Haematol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1346-8138.12419","article-title":"Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis","volume":"41","author":"Yonekura","year":"2014","journal-title":"J Dermatol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response","volume":"29","author":"Chen","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2340\/00015555-2555","article-title":"CD8+ T-cell-mediated interface dermatitis after CCR4+ T-cell depletion by mogamulizumab treatment of adult T-cell leukaemia\/lymphoma","volume":"97","author":"Ito","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ced.13539","article-title":"CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia\/lymphoma","volume":"43","author":"Tani","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2340\/00015555-2421","article-title":"Cutaneous adverse reaction to mogamulizumab may indicate favourable prognosis in adult T-cell leukaemia-lymphoma","volume":"96","author":"Yonekura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/1346-8138.13738","article-title":"Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity","volume":"44","author":"Kanno","year":"2017","journal-title":"J Dermatol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-2575","article-title":"Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemia-lymphoma","volume":"25","author":"Suzuki","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.14797","article-title":"Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms","volume":"32","author":"Masuda","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-2257","article-title":"Emergence of photosensitivity with decreased Treg cells in a patient with mycosis fungoides treated with anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"96","author":"Tatsuno","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2340\/00015555-2027","article-title":"Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient","volume":"95","author":"Honda","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R20-20230922","first-page":"e247","article-title":"Depletion of regulatory FoxP3","volume":"58","author":"Amakata","year":"2019","journal-title":"Int J Dermatol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2353\/jmoldx.2010.090123","article-title":"Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses","volume":"12","author":"Zhang","year":"2010","journal-title":"J Mol Diagn"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","article-title":"Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma","volume":"5","author":"Weng","year":"2013","journal-title":"Sci Transl Med"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","article-title":"TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Transl Med"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.semdp.2016.12.006","article-title":"Psoriasiform dermatitides: A brief review","volume":"34","author":"Wick","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2019.06.004","article-title":"The interface reaction pattern in the skin: an integrated review of clinical and pathological features","volume":"91","author":"Deschaine","year":"2019","journal-title":"Hum Pathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/DAD.0b013e3181722ef4","article-title":"Pattern analysis of drug-induced skin diseases","volume":"30","author":"Justiniano","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/DAD.0b013e31820a285d","article-title":"Histopathologic features of exanthematous drug eruptions of the macular and papular type","volume":"33","author":"Naim","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00000478-199407000-00001","article-title":"The histologic spectrum of mycosis fungoides\/S\u00e9zary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes","volume":"18","author":"Shapiro","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00000372-198812000-00001","article-title":"Light-microscopic assessment of 100 patients with patch\/plaque-stage mycosis fungoides","volume":"10","author":"Nickoloff","year":"1988","journal-title":"Am J Dermatopathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/modpathol.3880304","article-title":"Reassessment of lymphocytic atypia in the diagnosis of mycosis fungoides","volume":"14","author":"Yeh","year":"2001","journal-title":"Mod Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0560.2001.028004174.x","article-title":"Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting","volume":"28","author":"Guitart","year":"2001","journal-title":"J Cutan Pathol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/10428194.2018.1543887","article-title":"Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?","volume":"60","author":"Ansell","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/10428194.2018.1526376","article-title":"CD4+\/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides","volume":"60","author":"Husnain","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood-2017-11-814194","article-title":"Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8(+)","volume":"131","author":"Braue","year":"2018","journal-title":"Blood"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjd.14723","article-title":"Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides","volume":"175","author":"Endo","year":"2016","journal-title":"Br J Dermatol"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2133.2009.09541.x","article-title":"Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant","volume":"162","author":"Okada","year":"2010","journal-title":"Br J Dermatol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cup.12252","article-title":"Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases","volume":"41","author":"Aung","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"228.e2","DOI":"10.1016\/j.jaad.2015.04.030","article-title":"T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides","volume":"73","author":"Sufficool","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/ACI.0b013e328355b865","article-title":"Immunological mechanisms of epidermal damage in toxic epidermal necrolysis","volume":"12","author":"Tohyama","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e31826205d6","article-title":"Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions","volume":"94","author":"Mavin","year":"2012","journal-title":"Transplantation"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13535","article-title":"Regulatory T cells in autoimmune skin diseases","volume":"28","author":"Ujiie","year":"2019","journal-title":"Exp Dermatol"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2018.0884","article-title":"Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"154","author":"Dai","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R47-20230922","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"key":"R48-20230922","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T23:00:15Z","timestamp":1695423615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001587","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}